This post was originally published on this site
Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business.
The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don’t fall apart, the people said.
